[1]刘秋松,梅雀林,何晓峰,等.索拉非尼联合PVA微粒化疗栓塞治疗肝癌并肝动-静脉分流的疗效及预后分析[J].介入放射学杂志,2016,(04):320-324.
　LIU Qiu- song,MEI Que- lin,HE Xiao- feng,et al.Sorafenib plus percutaneous chemoembolization with polyvinyl alcohol for hepatocellular carcinoma complicated by hepatic arteriovenous shunts： analysis of curative effect and prognosis[J].journal interventional radiology,2016,(04):320-324.
点击复制

索拉非尼联合PVA微粒化疗栓塞治疗肝癌并肝动-静脉分流的疗效及预后分析 ()

PDF下载中关闭

分享到：

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
期数:
2016年04期
页码:
320-324
栏目:
肿瘤介入
出版日期:
2016-04-25

文章信息/Info

Title:
Sorafenib plus percutaneous chemoembolization with polyvinyl alcohol for hepatocellular carcinoma complicated by hepatic arteriovenous shunts： analysis of curative effect and prognosis
作者:
刘秋松;  梅雀林;  何晓峰;  曾庆乐;  庞桦进;  肖利军
Author(s):
LIU Qiu- song;  MEI Que- lin;  HE Xiao- feng;  ZENG Qing- le;  PANG Hua- jin;  XIAO Li- jun
Department of Interventional Radiology， Affiliated Nanfang Hospital， Southern Medical University， Guangzhou， Guangdong Province 510515， China
关键词:
【关键词】 索拉非尼;  化疗栓塞; 治疗性;  癌; 肝细胞;  肝动-脉静脉分流;  疗效;  预后分析
文献标志码:
A
摘要:
【摘要】 目的 评价索拉非尼联合PVA化疗栓塞（PVA- TACE）治疗肝癌合并肝动-静脉分流（HAVS）的疗效及预后因素。方法 110例肝癌合并HAVS患者，采用索拉非尼+PVA- TACE治疗（治疗组）17例，PVA- TACE治疗（对照组）93例。依据HAVS的分流速度，采用不同大小的PVA化疗栓塞分流道。随访并分析生存期、并发症等。采用Kaplan- Meier法计算累计生存率，预后因素采用Cox模型分析。结果 治疗组与对照组中位生存期（overall survival，OS）分别为12.8个月和7.7个月，两组有统计学意义（χ2=3.907，P=0.048）。两组6、12个月生存率分别为78.8%、45.5%，66.7%、23.6%。多因素分析结果显示：联合索拉非尼（HR=0.351，P=0.007）及多次栓塞（HR=0.498，P=0.018）为独立保护因素，术前AFP≥400 ng/ml（HR=1.984，P=0.018）为独立危险因素。结论 索拉非尼联合PVA- TACE治疗中晚期肝癌并HAVS安全、有效，疗效优于单纯PVA- TACE；术前AFP低表达及多次栓塞治疗患者的预后较好。

参考文献/References:

［1］ Ngan H, Peh WC. Arteriovenous shunting in hepatocellular carci- noma: its prevalence and clinical significance［J］. Clin Radiol, 1997, 52: 36- 40.
［2］ Oh D, Shin SW, Park HC, et al. Changes in arterioportal shunts in hepatocellular carcinoma patients with portal vein thrombosis who were treated with chemoembolization followed by radiotherapy［J］. Cancer Res Treat, 2015, 47: 251- 258.
［3］ 孙 磊， 施海彬， 刘 圣， 等． 肝细胞癌肝动脉门静脉分流形成的相关因素分析［J］． 介入放射学杂志， 2012， 21： 206- 210．
［4］ Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma［J］. N Engl J Med, 2008, 359: 378- 390.
［5］ Bruix J, Sherman M, American Association for the Study of Liver Diseases.Management of hepatocellular carcinoma: an update［J］. Hepatology, 2011, 53: 1020- 1022.
［6］ Kim YJ, Lee HG, Park JM, et al. Polyvinyl alcohol embolization adjuvant to oily chemoembolization in advanced hepatocellular carcinoma with arterioportal shunts［J］. Korean J Radiol, 2007, 8: 311- 319.
［7］ Mei Q, Li Y. Transcatheter arterial embolization of hepatic arterio- venous shunts in patients with hepatocellular carcinoma［J］. Semin Intervent Radiol, 2012, 29: 237- 240.
［8］ Lencioni R, Llovet JM. Modified RECIST（mRECIST） assessment for hepatocellular carcinoma［J］. Semin Liver Dis, 2010, 30: 52- 60.
［9］ Chung YH, Han G, Yoon JH, et al. Interim analysis of START: Study in Asia of the combination of TACE （transcatheter arterial chemoembolization） with sorafenib in patients with hepatocellular carcinoma trial［J］. Int J Cancer, 2013, 132: 2448- 2458.
［10］ Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia- Pacific region with advanced hepatocellular carcinoma: a phase Ⅲ randomised, double- blind, placebo- controlled trial［J］. Lancet Oncol, 2009, 10: 25- 34.
［11］ Choi GH, Shim JH, Kim MJ, et al. Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced- stage hepatocellular carcinoma: results of propensity score analyses［J］. Radiology, 2013, 269: 603- 611.
［12］ Abdel- Rahman O, Elsayed ZA. Combination trans arterial chemo- embolization（TACE） plus sorafenib for the management of unre- sectable hepatocellular carcinoma: a systematic review of the literature［J］. Dig Dis Sci, 2013, 58: 3389- 3396.
［13］ Zhu K, Chen J, Lai L, et al. Hepatocellular carcinoma with portal vein tumor thrombus: treatment with transarterial chemoembo- lization combined with sorafenib: a retrospective controlled study［J］. Radiology, 2014, 272: 284- 293.
［14］ Zheng J, Shao G, Luo J. Analysis of survival factors in patients with intermediate- advanced hepatocellular carcinoma treated with transcatheter arterial chemoembolization combined with sorafenib［J］. Clin Transl Oncol, 2014, 16: 1012- 1017.
［15］ 张璐西， 施海彬， 刘 圣， 等． TACE联合索拉非尼治疗BCLC- C期肝细胞癌20例疗效分析［J］． 介入放射学杂志， 2014， 23： 954- 958．
［16］ Chao Y, Chung YH, Han G, et al. The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: final results of the START trial［J］. Int J Cancer, 2015, 136: 1458- 1467.
［17］ Shi HB, Yang ZQ, Liu S, et al. Transarterial embolization with cyanoacrylate for severe arterioportal shunt complicated by hepatocellular carcinoma［J］. Cardiovasc Intervent Radiol, 2013, 36: 412- 421.
［18］ Theysohn JM, Schlaak JF, Muller S, et al. Selective internal radiation therapy of hepatocellular carcinoma: potential hepato- pulmonary shunt reduction after sorafenib administration［J］. J Vasc Interv Radiol, 2012, 23: 949- 952.
［19］ 毕新宇， 阎 涛， 赵 宏， 等． 甲胎蛋白水平与肝细胞癌预后的相关性分析［J］． 中华医学杂志， 2014， 94： 2645- 2649．
［20］ Brown DB, Cardella JF, Sacks D, et al. Quality improvement guidelines for transhepatic arterial chemoembolization, emboli- zation, and chemotherapeutic infusion for hepatic malignancy［J］. J Vasc Interv Radiol, 2006, 17: 225- 232.

相似文献/References:

[1]方 瑜,龙清云,刘骏方,等.肝癌合并肝动脉-肝门静脉瘘介入治疗方式的探讨[J].介入放射学杂志,2010,(10):776.
　FANG Yu,LONG Qing-yun,LIU Jun-fang,et al.Exploration of interventional therapeutic pattern for hepatocellular carcinoma associated with hepatic arterioportal fistulae[J].journal interventional radiology,2010,(04):776.
[2]邱伟利,王成刚.肝动脉化疗栓塞治疗转移性肝癌25例分析[J].介入放射学杂志,1997,(03):146.
[3]李茂全.胃癌介入治疗的现状和研究进展[J].介入放射学杂志,1999,(01):54.
[4]张绪敬,程佩芳,董光,等.原发性肝癌经导管化疗、栓塞前后血中凝血酶原变化的研究[J].介入放射学杂志,1992,(01):33.
[5]周文群,刘子江,袁建华,等.动脉内顺铂微球碘化油与抗癌药物碘化油栓塞化疗对肝癌疗效的比较[J].介入放射学杂志,1992,(01):27.
[6]李茂全,颜志平,周康荣,等.中晚期肝癌根治术后介入放射学治疗的临床研究[J].介入放射学杂志,1994,(02):79.
[7]刘古燕,金琰,王树森,等.肠系膜下动脉化疗栓塞致肛门括约肌松驰一例[J].介入放射学杂志,1994,(03):180.
[8]俞进友,朱良志,夏曙祥,等.肝动栓塞治疗肝癌并发癌破裂二例[J].介入放射学杂志,1994,(04):188.
[9]陈雪萍,程永德.肝癌肝动脉化疗栓塞术后影响甲胎蛋白下降因素探讨[J].介入放射学杂志,1995,(02):73.
[10]郝楠馨,贾雨辰,陈庆华,等.甲氨蝶呤明胶微球经肝动脉灌注后近期毒性的实验研究[J].介入放射学杂志,1995,(03):154.

备注/Memo

备注/Memo:
（收稿日期：２０１5-０7-3０）
（本文编辑：俞瑞纲）
更新日期/Last Update: 2016-04-21